385 related articles for article (PubMed ID: 31905765)
1. Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.
Khan HY; Ge J; Nagasaka M; Aboukameel A; Mpilla G; Muqbil I; Szlaczky M; Chaker M; Baloglu E; Landesman Y; Mohammad RM; Azmi AS; Sukari A
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905765
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells.
Kawamura Y; Saijo K; Imai H; Ishioka C
Cancer Sci; 2021 Nov; 112(11):4711-4721. PubMed ID: 34328666
[TBL] [Abstract][Full Text] [Related]
3. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
[TBL] [Abstract][Full Text] [Related]
6. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.
Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS
Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
9. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
[TBL] [Abstract][Full Text] [Related]
10. Non‑invasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using small‑animal FDG‑PET/CT.
Aoyama M; Takizawa H; Otani T; Inoue S; Kawakita N; Tsuboi M; Bando Y; Uehara H; Kondo K; Tangoku A
Oncol Rep; 2020 Oct; 44(4):1709-1716. PubMed ID: 32945510
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G
Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
[No Abstract] [Full Text] [Related]
13. Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells.
Ohno K; Shibata T; Ito KI
Cancer Sci; 2022 Sep; 113(9):3193-3210. PubMed ID: 35723021
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
Yeung KT; Cohen EE
Clin Cancer Res; 2015 Dec; 21(24):5420-6. PubMed ID: 26487760
[TBL] [Abstract][Full Text] [Related]
15. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
Garg M; Kanojia D; Mayakonda A; Ganesan TS; Sadhanandhan B; Suresh S; S S; Nagare RP; Said JW; Doan NB; Ding LW; Baloglu E; Shacham S; Kauffman M; Koeffler HP
Sci Rep; 2017 Aug; 7(1):9749. PubMed ID: 28852098
[TBL] [Abstract][Full Text] [Related]
16. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
[No Abstract] [Full Text] [Related]
17. Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.
Yang J; Bill MA; Young GS; La Perle K; Landesman Y; Shacham S; Kauffman M; Senapedis W; Kashyap T; Saint-Martin JR; Kendra K; Lesinski GB
PLoS One; 2014; 9(7):e102983. PubMed ID: 25057921
[TBL] [Abstract][Full Text] [Related]
18. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.
Wettersten HI; Landesman Y; Friedlander S; Shacham S; Kauffman M; Weiss RH
PLoS One; 2014; 9(12):e113867. PubMed ID: 25461627
[TBL] [Abstract][Full Text] [Related]
19. PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.
Wong K; Di Cristofano F; Ranieri M; De Martino D; Di Cristofano A
Endocr Relat Cancer; 2019 Apr; 26(4):425-436. PubMed ID: 30699064
[TBL] [Abstract][Full Text] [Related]
20. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
